Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, representing an 11% year-over-year increase on a GAAP basis and a 10% increase on a constant currency basis [6][7] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7][18] - Non-GAAP EPS grew by 12% year-over-year, exceeding expectations [8] - Free cash flow for Q4 was $74 million, up 13% year-over-year, marking a quarterly record for the company [8][19] - For the full year 2025, the company achieved constant currency revenue growth of 11% and generated nearly $216 million in free cash flow, up 16% year-over-year [19][20] Business Line Data and Key Metrics Changes - Q4 total revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, with organic growth driven by strong sales in EP, CRM, angiography, and access products [11][12] - Peripheral Intervention products sales increased by 13%, primarily driven by strong sales in Radar Localization and delivery systems [13] - Sales of custom procedural solutions products increased by 4%, while OEM products sales decreased by 15% [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales increased by 6% [16] - U.S. organic constant currency sales growth was 8%, and international organic constant currency sales growth was 4% [16] Company Strategy and Development Direction - The company aims to drive strong execution globally and successfully complete its Continued Growth Initiatives program, targeting a 5%-7% organic constant currency revenue CAGR for the three-year period ending December 31, 2026 [9][37] - The divestiture of the DualCap product line is expected to create additional manufacturing capacity and free up resources for higher-margin products [24][38] - The company is focused on both internal product innovation and strategic M&A to enhance its competitive position [36][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the dynamic global macro environment but expressed confidence in the company's strong execution and commitment to financial targets [9][19] - The company expects solid constant currency growth and non-GAAP operating margin expansion in 2026, despite potential headwinds from tariffs and trade policies [22][25] Other Important Information - The company introduced financial guidance for 2026, projecting total GAAP net revenue growth of 6%-8% year-over-year and free cash flow of at least $200 million [22][27] - The expected impact of tariffs on non-GAAP EPS for 2026 is approximately $0.19 per share [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management emphasized the importance of mix, pricing, cost discipline, and SKU rationalization to drive gross margin improvements [42][44] Question: How is the WRAPSODY product performing in the outpatient setting? - Management acknowledged that initial revenue expectations for WRAPSODY were missed but expressed confidence in achieving the $7 million revenue target for 2026 [46][48] Question: What factors are influencing the guidance for free cash flow in 2026? - Management indicated that the guidance reflects a conservative approach due to timing-based factors and ongoing capital expenditures [52][54] Question: What areas is the company looking at for potential M&A? - The company is focusing on both foundational and therapeutic products, seeking strategic opportunities that align with its growth drivers [56][59] Question: What is the outlook for the OEM business? - Management noted that the OEM business is expected to normalize to mid-to-high single-digit growth, despite recent inventory destocking [62][63]

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, an 11% increase year-over-year on a GAAP basis and a 10% increase on a constant currency basis [6][7] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7][18] - Non-GAAP EPS grew by 12%, exceeding expectations, with Q4 net income at $62.5 million or $1.04 per share, compared to $56.3 million or $0.93 per share in the prior period [8][18] - Free cash flow for Q4 was $74 million, a 13% increase year-over-year, marking a quarterly record for the company [8][19] Business Line Data and Key Metrics Changes - Total revenue growth in Q4 was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, while Peripheral Intervention products sales increased by 13% [12][13] - Sales of custom procedural solutions products increased by 4%, driven by high teens growth in kit sales [14] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales increased by 6% [16] - U.S. organic constant currency sales growth was 8%, while international organic constant currency sales growth was 4% [16] Company Strategy and Development Direction - The company aims for solid constant currency growth and non-GAAP operating margin expansion for 2026, with a focus on executing its Continued Growth Initiatives program [9][10] - The divestiture of the DualCap product line is expected to create additional manufacturing capacity and free up resources for higher-margin products [24][38] - The company is prioritizing research and development efforts and is open to strategic M&A to enhance its competitive position [38] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the dynamic global macro environment but expressed confidence in the company's execution and financial targets [9][10] - The CEO emphasized the importance of a listening tour to gather feedback and enhance the company's foundation for success [30][31] - The company is optimistic about its future based on strong product innovation and strategic acquisitions [36][38] Other Important Information - The company generated nearly $216 million of free cash flow in 2025, up 16% year-over-year, exceeding guidance expectations [19][20] - The balance sheet as of December 31, 2025, showed cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million [21] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management highlighted the focus on product mix, pricing, cost discipline, and ongoing SKU rationalization as key drivers for gross margin improvement [42][44][45] Question: How is the WRAPSODY product performing in the outpatient setting? - Management acknowledged that initial revenue expectations for WRAPSODY were missed but expressed confidence in achieving the $7 million revenue target for 2026 [46][48][49] Question: What factors are influencing the guidance for free cash flow in 2026? - Management indicated that the guidance reflects a conservative approach, considering ongoing capital expenditures and timing-related factors [52][54] Question: What areas is the company looking at for potential M&A? - The company is focusing on both foundational and therapeutic products, seeking strategic opportunities that align with its growth drivers [56][57][59] Question: What is the outlook for the OEM business? - Management noted that the OEM business is expected to normalize to mid-to-high single-digit growth, despite recent inventory destocking [62][63] Question: What are the expectations for growth in China? - Management indicated that growth in China was down year-over-year, primarily due to volume-based purchasing impacts, but remains optimistic about future improvements [78][79]

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, an 11% increase year-over-year on a GAAP basis and a 10% increase on a constant currency basis [5][6] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7] - Non-GAAP EPS grew by 12%, exceeding expectations, and free cash flow reached $74 million, a 13% increase year-over-year [8][19] - For the full year 2025, constant currency revenue growth was 11%, with a non-GAAP operating margin of 20.3% and free cash flow exceeding $215 million [9][19] Business Line Data and Key Metrics Changes - Q4 revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, while Peripheral Intervention products saw a 13% increase [11][12] - Sales of OEM products decreased by 15%, attributed to inventory destocking and macroeconomic factors [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales grew by 6% [16] - Organic constant currency growth in the U.S. was 8%, and 4% internationally [16] Company Strategy and Development Direction - The company aims for solid constant currency growth and non-GAAP operating margin expansion in 2026, with a focus on executing its Continued Growth Initiatives program [9][10] - The divestiture of the DualCap product line is expected to enhance manufacturing capacity and free up resources for higher-margin products [24][40] - The company is prioritizing R&D efforts and exploring M&A opportunities to drive growth [39][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the global macro environment but expressed optimism about the company's performance and future growth [9][10] - The CEO emphasized the importance of internal feedback and engagement with stakeholders to inform strategic decisions [30][33] Other Important Information - The company expects free cash flow of at least $200 million in 2026, with planned capital expenditures of approximately $90 million [27][55] - The anticipated impact of tariffs on non-GAAP EPS for 2026 is approximately $15 million [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management highlighted the focus on product mix, pricing discipline, and cost management as key drivers for gross margin improvement [43][46] Question: How is the WRAPSODY product performing in the market? - Management acknowledged that initial revenue expectations for WRAPSODY were not met but expressed confidence in achieving the $7 million revenue target for 2026 [48][50] Question: What are the strategic areas for M&A? - The company is looking at both foundational and therapeutic products for potential acquisitions, aiming to fill gaps in their product offerings [58][59] Question: What is the impact of the DualCap divestiture on margins and EPS? - The divestiture is expected to have a minimal EPS impact but will create a 140 basis point headwind to revenue growth [81][84]

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) reported strong first-quarter 2025 results with adjusted earnings per share (EPS) of 86 cents, reflecting a 14.7% increase year over year, surpassing the Zacks Consensus Estimate by the same percentage [1][2] Revenue Summary - Total revenues reached $355.4 million, up 9.8% year over year, exceeding the Zacks Consensus Estimate by 0.9% [2] - Revenues at constant exchange rate (CER) increased by 10.9% year over year, while organic revenues rose by 6% [2] - Revenue contributions included $9.2 million from the acquisition of Cook Medical's lead management product portfolio and $6.6 million from EndoGastric Solutions' assets [2] Geographic Performance - U.S. sales were $213.6 million, a 14.8% increase year over year, surpassing projections of $207 million [4] - International sales totaled $141.8 million, up 3.2% year over year, slightly below the projection of $144.4 million [4] - Asia-Pacific revenues were $62.6 million, down 0.5% year over year, while Europe, the Middle East, and Africa revenues were $63.3 million, up 3.7% [5] - Revenues from the Rest of World region were $15.9 million, reflecting a 17.7% increase year over year [6] Segment Performance - The Cardiovascular segment reported revenues of $338.7 million, an 8.1% increase year over year [7] - Peripheral Intervention (PI) revenues were $137.3 million, up 5.5%, while Cardiac Intervention (CI) revenues rose 10.6% to $99.7 million [8] - Custom Procedural Solutions (CPS) revenues declined 1.2% to $47.9 million, while OEM revenues improved 20.5% to $53.8 million [9][10] - Endoscopy devices generated revenues of $16.6 million, a significant increase of 64.2% year over year [10] Margin Analysis - Gross profit increased by 13.4% to $172 million, with gross margin expanding by 151 basis points to 48.4% [11] - Selling, general & administrative expenses rose 13.8% to $107.5 million, while research and development expenses increased by 4.6% to $22.5 million [11] - Adjusted operating profit totaled $42.1 million, reflecting a 17.5% increase, with an adjusted operating margin of 11.8% [12] Financial Position - Cash and cash equivalents at the end of the first quarter were $395.5 million, up from $376.7 million at the end of 2024 [13] - Total long-term debt was $730.7 million, slightly up from $729.6 million at the end of 2024 [13] - Net cash provided by operating activities was $40.6 million, compared to $36.2 million a year ago [13] Guidance - MMSI projects net revenues for 2025 to be between $1.470 billion and $1.490 billion, reflecting an increase of 8.4-9.8% year over year [14] - Cardiovascular segment revenues are expected to be in the range of $1.397 billion to $1.415 billion, while Endoscopy segment revenues are projected between $73 million and $75 million [15][16] - Adjusted EPS for 2025 is now projected to be between $3.29 and $3.42, a decrease from previous guidance [17] Market Reaction and Future Outlook - Shares of MMSI fell nearly 4.9% in after-hours trading following the earnings report [3] - The company announced the U.S. commercial release of its Ventrax Delivery System and the enrollment of the first patient in a study for the Bloom Micro Occluder System, indicating potential growth opportunities [20] - However, lower revenues in the APAC region and CPS revenues were disappointing, with specific challenges noted in the Chinese market [21]

Company Overview - Merit Medical Systems, Inc. (MMSI) has launched the Ventrax Delivery System, aimed at enhancing precision and control in pulmonary interventions, reflecting the company's commitment to improving procedural efficiency and outcomes in interventional medicine [1][2] Product Details - The Ventrax Delivery System expands MMSI's electrophysiology and cardiac rhythm management (CRM) portfolio, addressing the clinical demand for safer and more reliable pulmonary access technologies [2] - The system facilitates retrograde aortic access for catheter-based procedures, allowing precise placement of diagnostic, mapping, or treatment catheters into the left ventricle through the aorta, improving procedural accuracy [8][9] - Key features include a 95-cm sheath for navigating to critical target zones, a low-profile transition for smooth insertion, and an angled tip for enhanced reach, providing greater control during complex procedures [9] Market Context - The global cardiac rhythm management devices market was estimated at $17.17 billion in 2024, projected to grow at a CAGR of 6.4% from 2025 to 2030, driven by the rising prevalence of cardiovascular diseases and technological innovations [10][11] - The demand for advanced diagnostic tools like the Ventrax Delivery System is expected to rise as lung cancer screening and minimally invasive procedures gain traction [4] Financial Performance - MMSI currently has a market capitalization of $5.44 billion and has surpassed earnings estimates for the last four quarters, delivering an average surprise of 8.1% [5]

Company Overview - Merit Medical Systems, Inc. is a global leader in healthcare technology, founded in 1987, focusing on the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [7]. Product Launch - The company announced the US commercial release of its Ventrax Delivery System, which is the latest addition to its electrophysiology (EP) and cardiac rhythm management (CRM) portfolio [1][2]. Product Features - The Ventrax Delivery System is designed to facilitate the placement of devices used in ablation procedures for treating ventricular tachycardia (VT), a condition that contributes to a significant number of sudden cardiac deaths in the US, estimated between 184,000 and 450,000 annually [3]. - Key features of the Ventrax system include a 95-cm sheath for accessing target locations, an ultralow-profile transition for smooth insertion, and an angled tip to enhance the reach of an ablation catheter [6]. Market Context - VT ablation is one of the fastest-growing areas in electrophysiology, with many physicians adopting retrograde aortic access for VT procedures, indicating a rising demand for effective access tools in this field [7].